伴复杂核型的原发性浆细胞白血病一例并文献复习  

Primary plasma cell leukemia with complex karyotype:report of one case and review of literature

作　　者：王娟 梁利杰 刘玉章 刘丽娜 王耀美 向谱 房佰俊 宋永平 Wang Juan;Liang Lijie;Liu Yuzhang;Liu Lina;Wang Yaomei;Xiang Pu;Fang Baijun;Song Yongping(Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China)

机构地区：[1]郑州大学附属肿瘤医院河南省肿瘤医院血液科,450008

出　　处：《白血病．淋巴瘤》2020年第7期419-422,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(81370661)。

摘　　要：目的观察以硼替佐米、地塞米松为基础的三联化疗序贯自体造血干细胞移植后应用来那度胺维持并间断行强化治疗的系列方案治疗原发性浆细胞白血病的效果。方法回顾性分析河南省肿瘤医院2018年4月收治的1例伴复杂核型的原发性浆细胞白血病患者的临床资料,并对相关文献进行复习。结果该患者接受多个周期以硼替佐米、地塞米松为基础的三联化疗方案序贯自体造血干细胞移植,然后应用来那度胺维持并间断行强化治疗,获得完全缓解,至截稿前无进展生存达18个月。结论以硼替佐米、地塞米松为基础的三联化疗方案序贯自体造血干细胞移植后应用来那度胺维持并间断行强化治疗的系列方案可能会改善原发性浆细胞白血病患者的预后,延长生存时间。Objective To observe the efficacy of the serial treatment with autologous hematopoietic stem cell transplantation after bortezomib and dexamethasone-based triple chemotherapy regimen and followed by lenalidomide and intermittent intensive therapy in primary plasma cell leukemia.Methods A retrospective analysis was made on the clinical data of one patient who was diagnosed as primary plasma cell leukemia with complex karyotype in April 2018 in Henan Cancer Hospital,and the relevant literature was reviewed.Results The patient received multiple cycles of bortezomib and dexamethasone-based triple chemotherapy regimen,then received autologous hematopoietic stem cell transplantation,lenalidomide and intermittent intensive therapy.The patient eventually achieved complete remission and the progression-free survival time was 18 months until the day before the deadline for this article.Conclusion The treatment with autologous hematopoietic stem cell transplantation after bortezomib and dexamethasone-based triple chemotherapy regimen and followed by lenalidomide and intermittent intensive therapy may improve the prognosis of patients with primary plasma cell leukemia and prolong the survival time.

关 键 词：白血病 浆细胞 造血干细胞移植 药物疗法 联合 来那度胺 

分 类 号：R733.7[医药卫生—肿瘤]